Ineffectiveness of infliximab CT-P13 for the treatment of scleromyxedema: A case report

Dermatol Ther. 2018 Mar;31(2):e12583. doi: 10.1111/dth.12583. Epub 2017 Dec 7.

Authors

Federica Arginelli¹, Alessia Paganelli¹, Franco Rongioletti², Giovanni Pellacani¹, Andrea Conti¹

Affiliations

¹ Dermatology Clinic, Azienda Ospedaliero-Universitaria Policlinico di Modena, Italy.
² Dermatology Clinic, AOU Cagliari, Cagliari, Italy.

PMID: 29214719
DOI: 10.1111/dth.12583

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antibodies, Monoclonal / therapeutic use*
Biological Products / adverse effects*
Biosimilar Pharmaceuticals / adverse effects*
Drug Substitution
Humans
Immunoglobulins, Intravenous / administration & dosage
Male
Middle Aged
Remission Induction
Scleromyxedema / diagnosis
Scleromyxedema / drug therapy*
Scleromyxedema / immunology
Treatment Failure
Tumor Necrosis Factor-alpha / antagonists & inhibitors
Tumor Necrosis Factor-alpha / immunology

Substances

Antibodies, Monoclonal
Biological Products
Biosimilar Pharmaceuticals
CT-P13
Immunoglobulins, Intravenous
Tumor Necrosis Factor-alpha